Literature DB >> 20813106

Effect of interferon-γ on inflammatory cytokine-induced bradykinin B1 receptor expression in human vascular cells.

Gérémy Abdull Koumbadinga1, Anick Désormeaux, Albert Adam, François Marceau.   

Abstract

The expression of the bradykinin B(1) receptor is strongly regulated in vascular tissue following injury, with little or no expression in healthy tissues. The present work aimed to verify whether primary human vascular cells (umbilical vein endothelial cells, umbilical artery smooth muscle cells) respond to tumor necrosis factor (TNF)-α and interferon (IFN)-γ by an upregulation of B(1) receptors and whether these pathways interact. B(1) receptor expression was quantified using a [(3)H]Lys-des-Arg(9)-bradykinin binding assay (cell surface protein) and RT-PCR (mRNA). A pharmacological approach exploiting several inhibitory drugs related to cytokine signaling was applied. The combined treatment with TNF-α and IFN-γ had a synergistic effect on B(1) receptor expression in both cell types, increasing primarily receptor abundance in both cell types (16 h) and mRNA concentration (4h) in endothelial cells. The synergistic effect of the IFN-γ-TNF-α combination was abated by drugs targeted at the signaling of either cytokine (for TNF-α: etanercept or the IκB kinase 2 inhibitor TPCA-1; for IFN-γ: neutralizing antibodies to IFN-γ, a pan-Jak inhibitor but not the Jak2 inhibitor AG490). Thus, Jak2 signaling may not be recruited by the IFN-γ receptors in vascular cells; however, Stat1 phosphorylation was correlated as expected to the effect of IFN-γ on B(1) receptor expression. Random migration was inhibited by the B(1) receptor agonist Lys-des-Arg(9)-bradykinin only in smooth muscle cells pretreated with the cytokine combination. The amplificatory effect of IFN-γ on TNF-α-induced bradykinin B(1) receptor expression is relevant to vasculopathies associated with T helper 1 cytokines.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20813106     DOI: 10.1016/j.ejphar.2010.08.008

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  Hemodialysis-Related Complement and Contact Pathway Activation and Cardiovascular Risk: A Narrative Review.

Authors:  Sarah C Skinner; Vimal K Derebail; Caroline J Poulton; Donna C Bunch; Prabir Roy-Chaudhury; Nigel S Key
Journal:  Kidney Med       Date:  2021-06-09

2.  Kinin B1 receptor deficiency protects mice fed by cafeteria diet from abnormal glucose homeostasis.

Authors:  Poliana E Correia; Clarissa B Gomes; Vinicius A Bandeira; Thais Marten; Gabriella R Natividade; Paula Merello; Erica Tozawa; Carlos T S Cerski; Alexandre Budu; Ronaldo Araújo; Bruno D Arbo; Maria Flávia M Ribeiro; Carlos C Barros; Fernando Gerchman
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

Review 3.  A comprehensive review on current understanding of bradykinin in COVID-19 and inflammatory diseases.

Authors:  Devasahayam Arokiar Balaya Rex; Neelanchal Vaid; K Deepak; Shobha Dagamajalu; T S Keshava Prasad
Journal:  Mol Biol Rep       Date:  2022-05-21       Impact factor: 2.742

4.  Endostatin inhibits bradykinin-induced cardiac contraction.

Authors:  Jumpei Yasuda; Lila Takada; Yuka Kajiwara; Muneyosi Okada; Hideyuki Yamawaki
Journal:  J Vet Med Sci       Date:  2015-06-05       Impact factor: 1.267

5.  The Role of Bradykinin Receptors in Hereditary Angioedema Due to C1-Inhibitor Deficiency.

Authors:  Wojciech Dyga; Aleksander Obtulowicz; Tomasz Mikolajczyk; Anna Bogdali; Pawel Dubiela; Krystyna Obtulowicz
Journal:  Int J Mol Sci       Date:  2022-09-07       Impact factor: 6.208

6.  Biotechnological Fluorescent Ligands of the Bradykinin B1 Receptor: Protein Ligands for a Peptide Receptor.

Authors:  Xavier Charest-Morin; François Marceau
Journal:  PLoS One       Date:  2016-02-04       Impact factor: 3.240

Review 7.  Pathophysiology and underlying mechanisms in hereditary angioedema.

Authors:  Alberto López Lera
Journal:  Balkan Med J       Date:  2021-03       Impact factor: 2.021

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.